Braeburn
Mike Derkacz leads Braeburn with passion and clarity, bringing 25 years of pharmaceutical industry experience to his role. Mike is an accomplished and highly successful leader, with deep expertise in building market-leading brands, conducting award-winning product launches, creating highly effective teams, and developing sound commercial strategies to sustain market leadership. Prior to Braeburn, he was Senior Vice President and Head of Global CNS for Teva’s Global Specialty Medicines business. During his tenure at Teva, he led the launch of Copaxone 40mg, considered one of the most successful product introductions in the multiple sclerosis category, and named the pharma industry “Brand of the Year”. He joined Teva through the acquisition of Cephalon, where he served as Vice President, CNS Business unit. He spent the first 15 years of his career at GlaxoSmithKline — where he assumed positions of increasing leadership and commercial responsibility for major CNS and Cardiovascular brands.
This person is not in any offices
Braeburn
Braeburn is dedicated to delivering solutions for people living with the serious consequences of opioid use disorder. They are committed to advancing next-generation therapies, with individualized dosing regimens and delivery options, to address the escalating disease burden of opioid use disorder faced by patients, healthcare professionals, payers and society.